Drug intelligence / Profile preview

tislelizumab + recombinant human endostatin

Development stage: Unknown
Lead developer: BeiGene
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Tislelizumab + recombinant human endostatin is a combination therapy being investigated for the treatment of non-small cell lung cancer (NSCLC). Tislelizumab is a programmed cell death 1 (PD-1) antibody that functions as an immune checkpoint inhibitor. Recombinant human endostatin (also known as Endostar) is a multiple-target angiogenesis inhibitor that blocks proliferation and abnormal angiogenesis of tumor endothelial cells by limiting endothelial cell proliferation and migration and inducing endothelial cell apoptosis.

Other names: rh-endostatin

Targets

PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on tislelizumab + recombinant human endostatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tislelizumab + recombinant human endostatin.